PT  - JOURNAL ARTICLE
AU  - Khavir A. Sharieff
AU  - David Duncan
AU  - Zobair Younossi
TI  - Advances in treatment of chronic hepatitis C: ‘Pegylated’ interferons
DP  - 2002 Feb 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 155--159
VI  - 69
IP  - 2
4099  - http://www.ccjm.org/content/69/2/155.short
4100  - http://www.ccjm.org/content/69/2/155.full
SO  - Cleve Clin J Med2002 Feb 01; 69
AB  - New regimens consisting of pegylated interferons plus ribavirin may produce a sustained virologic response in more than 50% of cases of chronic hepatitis C. In contrast, the combination of standard interferon alfa and ribavirin, which was the standard of care until recently, produced a sustained virologic response in 35% to 40% of cases. As the efficacy of newer regimens improves, additional steps to adequately manage their side effects and maximize adherence may become crucial.